Literature DB >> 27569045

The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.

Gareth J Morgan1, Jeffery W Kelly2.   

Abstract

Light chain (LC) amyloidosis (AL amyloidosis) appears to be caused by the misfolding, or misfolding and aggregation of an antibody LC or fragment thereof and is fatal if untreated. LCs are secreted from clonally expanded plasma cells, generally as disulfide-linked dimers, with each monomer comprising one constant and one variable domain. The energetic contribution of each domain and the role of endoproteolysis in AL amyloidosis remain unclear. To investigate why only some LCs form amyloid and cause organ toxicity, we measured the aggregation propensity and kinetic stability of LC dimers and their associated variable domains from AL amyloidosis patients and non-patients. All the variable domains studied readily form amyloid fibrils, whereas none of the full-length LC dimers, even those from AL amyloidosis patients, are amyloidogenic. Kinetic stability-that is, the free energy difference between the native state and the unfolding transition state-dictates the LC's unfolding rate. Full-length LC dimers derived from AL amyloidosis patients unfold more rapidly than other full-length LC dimers and can be readily cleaved into their component domains by proteases, whereas non-amyloidogenic LC dimers are more kinetically stable and resistant to endoproteolysis. Our data suggest that amyloidogenic LC dimers are kinetically unstable (unfold faster) and are thus susceptible to endoproteolysis that results in the release amyloidogenic LC fragments, whereas other LCs are not as amenable to unfolding and endoproteolysis and are therefore aggregation resistant. Pharmacologic kinetic stabilization of the full-length LC dimer could be a useful strategy to treat AL amyloidosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AL amyloidosis; amyloid fibrils; endoproteolysis; immunoglobulin; systemic amyloidosis

Mesh:

Substances:

Year:  2016        PMID: 27569045      PMCID: PMC5065776          DOI: 10.1016/j.jmb.2016.08.021

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  59 in total

1.  Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.

Authors:  Jonathan S Wall; Vibha Gupta; Matthew Wilkerson; Maria Schell; Remy Loris; Paul Adams; Alan Solomon; Fred Stevens; Chris Dealwis
Journal:  J Mol Recognit       Date:  2004 Jul-Aug       Impact factor: 2.137

2.  Probing the role of λ6 immunoglobulin light chain dimerization in amyloid formation.

Authors:  Mathieu Laporte Wolwertz; Phuong Trang Nguyen; Noé Quittot; Steve Bourgault
Journal:  Biochim Biophys Acta       Date:  2016-01-21

3.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

4.  Folding of chymotrypsin inhibitor 2. 1. Evidence for a two-state transition.

Authors:  S E Jackson; A R Fersht
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

5.  Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

6.  Characterization of the thermal denaturation of Bence-Jones proteins by ultracentrifugation at elevated temperatures.

Authors:  K E Neet; F W Putnam
Journal:  J Biol Chem       Date:  1966-05-25       Impact factor: 5.157

Review 7.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

8.  Visible fluorescent detection of proteins in polyacrylamide gels without staining.

Authors:  Carol L Ladner; Jing Yang; Raymond J Turner; Robert A Edwards
Journal:  Anal Biochem       Date:  2004-03-01       Impact factor: 3.365

9.  Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.

Authors:  L R Helms; R Wetzel
Journal:  J Mol Biol       Date:  1996-03-22       Impact factor: 5.469

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

View more
  26 in total

1.  In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.

Authors:  Elena S Klimtchuk; Tatiana B Prokaeva; Brian H Spencer; Olga Gursky; Lawreen H Connors
Journal:  Amyloid       Date:  2017-06-20       Impact factor: 7.141

2.  The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains.

Authors:  Enrico Rennella; Gareth J Morgan; Nicholas Yan; Jeffery W Kelly; Lewis E Kay
Journal:  J Am Chem Soc       Date:  2019-08-14       Impact factor: 15.419

3.  Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein.

Authors:  Lars Plate; Bibiana Rius; Bianca Nguyen; Joseph C Genereux; Jeffery W Kelly; R Luke Wiseman
Journal:  Cell Chem Biol       Date:  2019-05-16       Impact factor: 8.116

4.  Role of domain interactions in the aggregation of full-length immunoglobulin light chains.

Authors:  Enrico Rennella; Gareth J Morgan; Jeffery W Kelly; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-31       Impact factor: 11.205

5.  Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Authors:  Gareth J Morgan; Nicholas L Yan; David E Mortenson; Enrico Rennella; Joshua M Blundon; Ryan M Gwin; Chung-Yon Lin; Robyn L Stanfield; Steven J Brown; Hugh Rosen; Timothy P Spicer; Virneliz Fernandez-Vega; Giampaolo Merlini; Lewis E Kay; Ian A Wilson; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

6.  Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?

Authors:  Gareth J Morgan; Grace A Usher; Jeffery W Kelly
Journal:  Biochemistry       Date:  2017-12-04       Impact factor: 3.162

7.  A kinetic coupling between protein unfolding and aggregation controls time-dependent solubility of the human myeloma antibody light chain.

Authors:  Veronika Džupponová; Veronika Huntošová; Gabriel Žoldák
Journal:  Protein Sci       Date:  2020-10-19       Impact factor: 6.725

Review 8.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins.

Authors:  Nicholas L Yan; Diogo Santos-Martins; Enrico Rennella; Brittany B Sanchez; Jason S Chen; Lewis E Kay; Ian A Wilson; Gareth J Morgan; Stefano Forli; Jeffery W Kelly
Journal:  Bioorg Med Chem Lett       Date:  2020-06-16       Impact factor: 2.823

10.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.